We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
CALL
Alkermes
ALKS
$8.47B
$3.92M 0.47%
676
-923
-58% -$54K
ESPR
27
CALL
DELISTED
Esperion Therapeutics
ESPR
$3.89M 0.46%
538
+423
+368% +$31.1K
GBT
28
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.66M 0.44%
+758
New +$42.3K
RKDA icon
29
Arcadia Biosciences
RKDA
$1.37M
$3.61M 0.43%
+3,763
New +$1.69M
ABBV icon
30
CALL
AbbVie
ABBV
$465B
$3.49M 0.42%
369
+344
+1,376% +$37.8K
ALNY icon
31
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
$2.98M 0.35%
250
-1,353
-84% -$174K
NKTR icon
32
PUT
Nektar Therapeutics
NKTR
$2.39B
$2.98M 0.35%
+19
New +$24.5K
ZGNX
33
PUT
DELISTED
Zogenix, Inc.
ZGNX
$2.75M 0.33%
687
-427
-38% -$16.9K
SGMO
34
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.7M 0.32%
+142,136
New +$3.04M
AMRN
35
CALL
Amarin Corp
AMRN
$293M
$2.5M 0.3%
416
+295
+244% +$21.9K
AVEO
36
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.49M 0.3%
857
+845
+7,042% +$24.7K
XLRN
37
PUT
DELISTED
Acceleron Pharma
XLRN
$2.05M 0.24%
+524
New +$22.3K
CTXR icon
38
Citius Pharmaceuticals
CTXR
$13.7M
$1.99M 0.24%
25,648
+17,243
+205% +$1.59M
AMRS
39
PUT
DELISTED
Amyris Inc.
AMRS
$1.89M 0.22%
2,821
+2,571
+1,028% +$13.8K
OTLK icon
40
Outlook Therapeutics
OTLK
$169M
$1.88M 0.22%
13,177
+181
+1% +$32.3K
AKAO
41
PUT
DELISTED
Achaogen Inc
AKAO
$1.82M 0.22%
+1,405
New +$15.9K
BMY icon
42
PUT
Bristol-Myers Squibb
BMY
$130B
$1.78M 0.21%
281
-34,401
-99% -$2.21M
CANF
43
Can-Fite BioPharma American Depositary Shares
CANF
$6.77M
$1.77M 0.21%
+409
New +$2.26M
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
$1.66M 0.2%
61,189
+182
+0.3% +$4.96K
NOVN
45
DELISTED
Novan, Inc. Common Stock
NOVN
$1.6M 0.19%
+54,515
New +$1.83M
QNRX
46
Quoin Pharmaceuticals
QNRX
$8.44M
$1.56M 0.19%
+2
New +$1.65M
FOLD
47
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.51M 0.18%
1,005
-9,366
-90% -$143K
FOLD
48
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.5M 0.18%
1,000
-1,000
-50% -$15.2K
PAVM icon
49
PAVmed
PAVM
$38.5M
$1.49M 0.18%
+2,020
New +$1.73M
BMY icon
50
Bristol-Myers Squibb
BMY
$130B
$1.47M 0.18%
23,312
-908,495
-97% -$58.4M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.